ECTRIMS2018 multiple sclerosis MS

Updates from the ECTRIMS 2018 Annual Meeting (#ECTRIMS18)

The ECTRIMS 2018 Annual Meeting was held from October 10 to 12 in Berlin, Germany. MediPaper has summarised some key papers from the conference.

Efficacy of Oral Cladribine in Multiple Sclerosis Durable after a 2-Year Course of Treatment

Efficacy of oral Cladribine for MS durable after a two-year treatment course

Two short courses of oral cladribine (Mavenclad®, Merck KGaA) over a period of two years can sustain the No Evidence of Disease Activity-3 (NEDA-3) status in certain relapsing-remitting multiple sclerosis (RRMS) patients for up to three additional years without further treatment, a new analysis presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2018 suggests.

Early treatment with ocrelizumab lowers 5-year brain atrophy-rates in MS

Early treatment with ocrelizumab lowers 5-year brain atrophy rates in MS

Relapsing multiple sclerosis (MS) patients initiating ocrelizumab (Ocrevus®, Roche/Genentech) two years earlier had significant reductions in 5-year brain atrophy rates when compared to those switching from interferon β-1a, as reported in the latest results from the OPERA studies’ extension phase.